Announcements
25 June 2024
Metabolites Receives an Updated Impact Factor of 3.4 and CiteScore of 5.7
We are pleased to share that Metabolites (ISSN: 2218-1989) was awarded an updated Impact Factor of 3.4 in the 2023 Journal Citation Reports™ released by Clarivate in June 2024. Metabolites ranks Q2 (138 among 313 titles) in the “Biochemistry & Molecular Biology” category.
Additionally, according to data released by Scopus (Elsevier), Metabolites received an updated CiteScore™ of 5.7, an increase of 7.5% compared with the 2022 metric.
Metabolites’ CiteScore ranks are as follows:
- Q2 (97 out of 244 journals) in the “Endocrinology, Diabetes and Metabolism” category;
- Q2 (215 out of 438 journals) in the “Biochemistry” category;
- Q2 (224 out of 410 journals) in the “Molecular Biology” category.
|
3.42023 Impact Factor |
138/313 (Q2)Biochemistry & Molecular Biology |
14,480Citations in 2023 |
|
5.72023 CiteScore |
97/244 (Q2)Endocrinology, Diabetes and Metabolism |
0.843SNIP |
For further statistics, please visit https://www.mdpi.com/journal/metabolites/stats. For more information about MDPI flagship journals' citation metrics, please see here.
At MDPI, our mission is simple yet powerful, and we strive every day to make scientific research freely accessible to everyone, everywhere. With over 3.5 million authors choosing MDPI, we have established ourselves as a key player driving the open access initiative.
Our journals have received over 13 million citations in the Web of Science, making us the most cited open access publisher. With over 800 institutional partners, MDPI continues to demonstrate its dedication to providing reliable and collaborative publishing services.
Metabolites Editorial Office
